Phase 1 Study of Coxsackievirus A21 for the treatment of melanoma

Intratumoural administration of coxsackievirus A21 for the control of malignant melanoma.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000636651

Enrollment

Registered

2005-10-13

Start date

2005-09-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

A single intratumoural injection of coxsackievirus A21.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Stage IV melanoma (AJCC)- minimum of 2 SC metastases- failure or refusal of standard chemotherapy- ECOG score of 0 or 1- other.

Exclusion criteria

Metastatic CNS disease- occular or mucosal melanoma- immunodeficiency- splenectomy- other.

Outcome results